Qigui Luobitong

Qigui Luobitong (also known as Qi Gui Luo Bi Tong or Luobitong) is a novel traditional Chinese medicine (TCM) formulation developed by Yiling Pharmaceutical. It is formulated as a tablet (芪桂络痹通片) and has also been studied as a capsule. Qigui Luobitong is composed of extracts from multiple botanicals, including Astragali Radix, Gentianae Macrophyllae Radix, Stephaniae Tetrandrae Radix, Radix Aconiti Praeparata, Polygoni Cuspidati Rhizoma Et Radix, Spatholobi Caulis, Clematidis Radix Et Rhizoma, Sinapis Semen, Paeoniae Radix Alba, Rehmanniae Radix, Angelicae Sinensis Radix, Myrrha, Cyperi Rhizoma, Cinnamomi Ramulus, and Cyathulae Radix. It is primarily developed for the treatment of rheumatoid arthritis (specifically wind-cold-damp-arthritis syndrome). Mechanistically, Qigui Luobitong exerts anti-inflammatory, analgesic, and immunomodulatory effects by targeting multiple inflammatory pathways, including the regulation of macrophage polarization, inhibition of the NF-κB and MAPK signaling pathways, and suppression of Th17 cell expression and downstream cytokines like IL-17A. As of late 2026, its New Drug Application (NDA) is under review by the National Medical Products Administration (NMPA) in China.